Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 30.20 INR
Change Today 0.00 / 0.00%
Volume 0.0
PDI On Other Exchanges
Symbol
Exchange
PDI is not on other exchanges.
As of 7:06 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

parenteral drugs india ltd (PDI) Snapshot

Open
31.40
Previous Close
30.40
Day High
31.40
Day Low
29.00
52 Week High
08/12/15 - 34.00
52 Week Low
03/27/15 - 16.10
Market Cap
900.5M
Average Volume 10 Days
27.4K
EPS TTM
-22.68
Shares Outstanding
29.8M
EX-Date
09/13/10
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PARENTERAL DRUGS INDIA LTD (PDI)

Related News

No related news articles were found.

parenteral drugs india ltd (PDI) Related Businessweek News

No Related Businessweek News Found

parenteral drugs india ltd (PDI) Details

Parenteral Drugs (India) Limited operates as a healthcare company in India and internationally. It is involved in the research, production, and manufacturing of pharmaceutical products, including intravenous infusion products, tablets, capsules, liquids syrups, injections, etc., as well as oncology and critical care products. The company was founded in 1983 and is based in Indore, India.

Founded in 1983

parenteral drugs india ltd (PDI) Top Compensated Officers

Managing Director and Director
Total Annual Compensation: 1.5M
Chief Executive and Whole-Time Director
Total Annual Compensation: 1.5M
Whole-Time Director
Total Annual Compensation: 1.3M
Compensation as of Fiscal Year 2015.

parenteral drugs india ltd (PDI) Key Developments

Parenteral Drugs (India) Limited Announces Relocation of Plant

Parenteral Drugs (India) Limited announced that the company has initiated the process of relocation of the plant situated at Village Asrawad, Post Dudhia, Nemawar Road, Indore, Madhya Pradesh to Village Panwa, Tehsil Kasrawad, District Khargone, Madhya Pradesh in April 2015 and for the purpose of relocation of the same, since, the civil work has almost been completed for its IV Fluids and allied manufacturing activities, the company has discontinued its manufacturing operations at Village Asrawad with effect from August 24, 2015. The company will inform the commencement of manufacturing operations at the newly established plant situated at Village Panwa, Tehsil Kasrawad, DistrictKhargone, Madhya Pradesh in due course.

Parenteral Drugs (India) Limited Reports Unaudited Standalone and Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Parenteral Drugs (India) Limited reported unaudited standalone and consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, on standalone basis the company reported a net loss of INR 144.308 million compared to INR 175.776 million for the quarter ended June 30, 2014. Net sales/income from operations was INR 509.476 million compared to INR 528.793 million for the quarter ended June 30, 2014. Profit operations before other income, finance costs and exceptional items was INR 0.169 million against loss of INR 24.484 million a year ago. Loss from ordinary activities before tax was INR 143.707 million against INR 166.587 million a year ago. Loss per share before and after extraordinary items was INR 4.84 against INR 5.90 a year ago. For the quarter, on consolidated basis the company reported a net loss of INR 172.284 million compared to INR 204.845 million for the quarter ended June 30, 2014. Net sales/income from operations was INR 880.481 million compared to INR 771.128 million for the quarter ended June 30, 2014. Profit operations before other income, finance costs and exceptional items was INR 11.309 million against loss of INR 30.418 million a year ago. Loss from ordinary activities before tax was INR 166.475 million against INR 195.656 million a year ago. Loss per share before and after extraordinary items was INR 5.78 against INR 6.87 a year ago.

Parenteral Drugs (India) Limited Demise of S.C. Consul, Independent Director

Parenteral Drugs (India) Limited has announced that there is a change in the company's directorate in terms of Clause 30(a) of the Listing Agreement due to death of Shri S.C. Consul, Independent Director of the company on July 14, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDI:IN 30.20 INR -0.20

PDI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PDI.
View Industry Companies
 

Industry Analysis

PDI

Industry Average

Valuation PDI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.3x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PARENTERAL DRUGS INDIA LTD, please visit www.pdindia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.